期刊文献+

国际上抗癌新药研究的概况 被引量:3

General situation of new anticancer drugs in development throughout the world
在线阅读 下载PDF
导出
摘要 查阅国内外相关文献,对目前国际上正处于临床研究阶段的399种抗癌新药进行归纳、综述和概括性介绍,并对诸如治疗肺癌、乳腺癌、前列腺癌和结直肠癌等的新药进行了重点介绍。这399种新药大致分为23个大类,有些是采用高新技术治疗癌症,有些则是探索现有药品的新靶点和新途径,以用于治疗其他癌症。 Based on the related literature at home and abroad, 399 new medicines for treating cancer throughout the world, especially for treating lung cancer, breast cancer, prostate cancer and colorectal carcinoma etc. , are reviewed. The 399 new medicines are classified into 23 categories. Some use high-tech for fighting diseases in new ways, and some involve research on new targets and ways to use existing medicines in treating other cancers.
出处 《药学服务与研究》 CAS CSCD 2006年第3期186-192,共7页 Pharmaceutical Care and Research
关键词 抗肿瘤药 药物 临床试用 综述 antineoplastie agents drugs, investigational review
  • 相关文献

参考文献15

  • 1399 new medicines in development to treat cancer[EB/OL].[2005 10-20].http://www.drugresearcher.com/news/ng.asp? id=60177.
  • 2安富荣,沈金芳.贝伐单抗治疗转移性结直肠癌研究进展[J].中国肿瘤生物治疗杂志,2005,12(2):158-160. 被引量:7
  • 3陆志城.贝伐单抗:一种治疗转移性结直肠癌的新药[J].中国处方药,2005,4(5):32-34. 被引量:3
  • 4399 medicines in development offer hope in the war on cancer[EB/OL].[2005-07-15].http://www.phrma.org/newmedicines/resources/2005-05-17.163.pdf.
  • 5WEIR H K,THUN M J,HANKEY B F,et al.Annual report to the nation on the status of cancer,1975-2000,featuring the uses of surveillance data for cancer prevention and control[J].J Natl Cancer Inst,2003,95(17);1276-1299.
  • 6EDWARDS B K,HOWE H L,RIEWS L A,et al.Annual report to the nation on the status of cancer,1973-1999,featuring implications of age and aging on U.S.cancer burden[J].Cancer,2002,94(10):2766-2792.
  • 7A.P.pharma announces submission of APF530 pivotal trial protocol for FDA review[EB/OL].[2005-10-25].http://www.leaddiscovery.co.uk/pr/pr24010606.html.
  • 8American Lung Association.Trends in lung cancer morbidity and mortality[EB/OL].[2005-11-10].http://www.lungusa.org /atf /cf /% 7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256 % 7D/1c1.pdf.
  • 9罗凤荣,李雁平.乳腺癌影像学诊断研究[J].医学综述,2005,11(9):856-858. 被引量:2
  • 10Breast cancer:statistics on incidence,survival,and screening[EB/OL].[2005-11-20].http://www.imaginis.com/breasthealth/statistics.asp.

二级参考文献30

  • 1卢铸,颜红兵.乳腺MR成象:现状与展望[J].国外医学(临床放射学分册),1995,18(3):159-161. 被引量:4
  • 2傅俊峰,曹小丽,殷伟红,赵永才,刘瑞华,朱桂荣.乳腺小肿块的高频超声和彩色多普勒超声探讨[J].中华超声影像学杂志,1997,6(3):166-168. 被引量:67
  • 3金显宅.乳腺癌的研究[M].天津科技出版社,1987.72.
  • 4Hagay C, Cherel PI, Maulmont CE, et al. Contrast-enhanced CT : value for diagnosing local breast cancer recurrence after conservative treatment[J]. Radiology, 1996,200(3) : 631-638.
  • 5Lister D, Evans AJ, Burrell HC, et al. The accuracy of breast ultrasound in the evaluation of clinically benign discrete, symptomatic breast lumps[ J ]. Clin Radiol, 1998,53 (7) : 490-492.
  • 6徐开野 唐迪.乳腺X线诊断学[M].上海:上海科学技术出版社,1980.45.
  • 7Hsei VC, Novotny WF, Margolin K, et al. Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects[J]. Proc Am Soc Clin Oncol, 2001, 20: 69a.
  • 8Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data [J]. J Clin Oncol, 2001, 19(4): 851-856.
  • 9Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2003, 21(1): 60-65.
  • 10Giantonio BJ, Levy D, O′Dwyer PJ, et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (adv-CRC): Results from the eastern cooperative oncology group (ECOG) study E2200[J]. Proc Am Soc Clin Oncol, 2003, 22: 255.

共引文献15

同被引文献40

  • 1岑洪译.抗肿瘤新药:首个VEGF抑制剂Bevacizumab上市[J].广西医学,2005,27(4):608-611. 被引量:10
  • 2杨震,孙国平.抑癌基因PTEN与原发性肝癌的研究进展[J].安徽医药,2006,10(2):85-87. 被引量:4
  • 3张明新.乳腺局限性腺体增厚与早期乳腺癌[J].实用诊断与治疗杂志,2006,20(4):297-299. 被引量:8
  • 4杜海洲,宋金燕,崔淑艳.反义药物的开发与研究进展[J].医药世界,2006(8):34-35. 被引量:1
  • 5陆宁(综述),佟仲生(审校).双重酪氨酸激酶抑制剂Lapatinib治疗乳腺癌研究进展[J].国际肿瘤学杂志,2007,34(5):362-365. 被引量:3
  • 6PhRMA. More than 700 medicines now in developnlent for major diseases affecting women[EB/OL]. [2008-01 -15]. http:// www. phrma, org/news _ room/pressreleases/more _ than _700 _ medicines_now_in_development for major_diseasesaffecting _women/.
  • 7Oporia (Lasofoxifene) -invesligational SERM for the prevention and treatment of osteoporosis[EB/OL]. [2008 -01 -20]. http://www. drugdevelopment-technology, com/projects/lasofoxifene.
  • 8PhRMA. More than 400 new medicines now in development for women; 62 for breast cancer a/one [ EB/OL].[2007 10 - 15 ]. hltp://www, phrma, org/news room/press_releases/more than_400 new,_ medicines now in development for_women;_ 62 for breast cancer alone/.
  • 9American Cancer Society. Caner facts & figures 2008 [ EB/OL]. [2008 - 02 - 16].http://www. cancer, org/downloads/STT/ 2008 CAFFfinal secured, pdf.
  • 10The Food and Drug Administralion. FDA approves Tykerb ( lapatinib tablets) for advanced metastatic breasl cancer patients[ EB/ OL]. [2008 -02 -28]. http://www.fda.gov/cder/Offices/OODP/w hatsnew/lapatinib, him.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部